Home › NDC Lookup › Ingredients › Dactylis Glomerata › 49643-0343-05
Standardized Orchard Grass Dactylis glomerata 100000 [BAU]/mL Injection, 5 mL — NDC 49643-0343-05 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Standardized Orchard Grass Dactylis glomerata 100000 [BAU]/mL Injection, 5 mL — NDC 49643-343-05 (Billing 49643-0343-05)

by Allermed Laboratories, Inc. · 5 mL in 1 VIAL, MULTI-DOSE

This is a package of 5 mL of Standardized Orchard Grass Dactylis glomerata 100000 [BAU]/mL Injection from Allermed Laboratories, Inc., marketed since Dec 1996 and currently FDA-listed. It is the main listing for this product, which comes in 4 package sizes.

NDC 49643-0343-05
🏷️ FDA NDC (as labeled) 49643-343-05 billing pads the product segment with a zero
This package
Contains5 mL Pack sizes4 compare ↓
Main listing for product 49643-343 · Also comes in: 10 ml 49643-343-10 30 ml 49643-343-30 50 ml 49643-343-50
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 49643-343-05 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
49643 labeler · 343 product · 05 package
Package marketed since
Dec 2, 1996
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 4964334305 2
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 49643-343-05
Product NDC 49643-343
11-digit billing NDC 49643034305
RxCUI 851873, 852157, 853027, 853047, 853278, 854054, 854162, 897496
UNII 175F461W10, 4T81LB52R0, 83N78IDA7P, A0WFQ8P6N1, SCB8J7LS3T, HU8V6E7HOA +2 more
Application # BLA102217
SPL Set ID d33c3aed-f487-45ed-a465-365170c6450a
Established class (EPC) Standardized Pollen Allergenic Extract; Non-Standardized Pollen Allergenic Extract
Physiologic effect Increased Histamine Release; Cell-mediated Immunity; Increased IgG Production
Chemical class Pollen; Allergens
DEA schedule Non-controlled
Marketing category BLA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1996-12-02
Route CUTANEOUS, INTRADERMAL, SUBCUTANEOUS
Dosage form INJECTION
Substance DACTYLIS GLOMERATA POLLEN
Biologic (Purple Book) 351(a)
Quick answers
  • RxCUI (RxNorm): 851873
Why two NDCs? The FDA registers this code as 49643-343-05 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 49643-0343-05. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 10 ml 30 ml 50 ml
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
49643-0343-05 You're viewing this Main listing 5 mL in 1 VIAL, MULTI-DOSE 1996-12-02 — Active
49643-0343-10 49643-343-10 10 mL in 1 VIAL, MULTI-DOSE 1996-12-02 — Active
49643-0343-30 49643-343-30 30 mL in 1 VIAL, MULTI-DOSE 1996-12-02 — Active
49643-0343-50 49643-343-50 50 mL in 1 VIAL, MULTI-DOSE 1996-12-02 — Active

You're viewing the smallest of 4 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This package contains 5 mL — 5 ml in 1 vial, multi-dose.
How does this package differ from NDC 49643-0343-10?
Both are Standardized Orchard Grass Dactylis glomerata 100000 [BAU]/mL Injection — the drug itself is identical. This page's package is the 5 mL one, while NDC 49643-0343-10 is the 10 ml package.
What NDC number is used to bill for this package of Standardized Orchard Grass Dactylis glomerata 100000 [BAU]/mL Injection?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Orchard Grass, Standardized 100000 [BAU]/mL 00268-0281-10 ALK-Abello, 10 ml — — FDA listed —
Orchard Grass, Standardized 100000 [BAU]/mL 00268-3055-06 ALK-Abello, 5 ml — — FDA listed —
Standardized Orchard Grass Pollen 100000 [BAU]/mL 22840-0206-02 Greer 10 ml — — FDA listed —
Standardized Orchard Grass 100000 [BAU]/mLthis 49643-0343-05 Allermed 5 ml — — FDA listed —
Standardized Grass Pollen, Orchard Grass 100000 [BAU]/mL 65044-0719-01 Jubilant 5 ml — — Discontinued —
About this product: this is a biologic. Biologics don't have small-molecule generics — competition comes from FDA-licensed biosimilars (shown above), not generics.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & biosimilar status

🏛️
1974
First FDA approval
Mar 1974
📍
2026
Currently FDA-listed
52 years listed
🧬
·
Biosimilars
see Purple Book
🧬Biologic — competition comes from biosimilars

Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.

Where does this data come from?
Patents and exclusivity from the FDA Purple Book (biologics), refreshed from public FDA data. Biosimilar launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • 0.53 mL / 1 mL UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • 0.004 g / 1 mL UNII 339NCG44TV
    Phenol is a chemical compound derived from coal tar or petroleum. It serves as a preservative and antimicrobial agent in medicines, helping prevent bacterial and fungal growth to keep the product stable and safe during storage.
  • 0.00125 g / 1 mL UNII 8MDF5V39QO
    A white powder form of baking soda that acts as a buffer and pH regulator in medicines. It helps maintain the right acid-base balance and may aid tablet disintegration.
  • 0.0025 g / 1 mL UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

5 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAllermed Laboratories, Inc.
FDA applicationBLA102217 (BLA)
Labeler code49643
First marketedDec 1996
Product typeHuman Prescription Drug
Portfolio199 products on file

More NDCs from Allermed Laboratories, Inc. labeler code 49643

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🚨 Boxed Warning 🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description ⚠️ Precautions 📚 References 📄 Package Label / Principal Display Panel
🚨 Boxed Warning ~1 min read ▾

WARNINGS This product is intended for use by physicians who are experienced in the administration of allergenic extract or for use under the guidance of an allergy specialist. In previously untreated patients, the initial dose must be based on skin testing as described in the dosage and administration section of this insert. Patients being switched from alum-adsorbed or other types of precipitated extracts to this extract should be started as though they were coming under treatment for the first time.

Patients should be instructed to recognize adverse reaction symptoms and cautioned to contact the physician's office if symptoms occur. As with all allergenic extracts, severe systemic reactions may occur and in certain individuals these reactions may be lifethreatening or cause death. Patients should be observed for at least 20 minutes following treatment.

Emergency measures as well as personnel trained in their use should be immediately available in the event of a life-threatening reaction. Patients being switched to a new lot of extract from the same manufacturer should have the dose reduced 75 percent. For dose selection in switching patients from unstandardized to standardized extract, physicians may refer to Table 3 as a guide (see CLINICAL PHARMACOLOGY).

Extracts labeled in BAU/mL are not directly interchangeable with any other grass pollen product. Patients receiving beta-blocking drugs may be refractive to the usual dose of epinephrine, in the event that epinephrine is required to control an adverse allergic reaction to this product. Caution must be exercised in testing and treating patients with steroid-dependent or labile asthma.

This product should never be injected intravenously. See also WARNINGS and ADVERSE REACTIONS below. Serious adverse reactions to this product should be reported to VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

🎯 Indications and Usage 209 words ▾

INDICATIONS AND USAGE Standardized grass pollen extract is indicated for use in the diagnosis of grass allergy in patients with a history of allergic symptoms that occur during grass pollination. Skin tests with standardized grass pollen extract should be done first by the puncture method using 10,000 BAU/mL extract. If these tests are negative, they may be repeated by the puncture method with 100,000 BAU/mL extract, or by the intradermal method using an appropriate dilution (see DOSAGE AND ADMINISTRATION).

The extract also is indicated for use in the treatment of allergic symptoms by immunotherapy in patients with a history of grass pollen allergy and established sensitivity to grass pollen extract by skin testing. The availability of 10,000 and 100,000 BAU/mL extracts facilitates dose selection for safe switching to standardized grass pollen extracts. Previously untreated patients should be initially treated with appropriately diluted 10,000 BAU/mL.

If tolerated, higher doses may be indicated. The use of grass pollen extract for the above purposes should be made only by physicians with special familiarity and knowledge of allergy as described in a standard allergy textbook (13). Allermed's standardized grass pollen extracts labeled in BAU/mL are not interchangeable with alum-precipitated grass pollen extracts, grass pollen extracts labeled in AU/mL or non-standardized grass pollen extracts.

⏱️ Dosage and Administration ~3 min read ▾

DOSAGE AND ADMINISTRATION Parental drug products should be inspected visually for particulate matter and discoloration prior to adminitration, whenever solution and container permit. The product should be discarded if discoloration or particles are observed. DIAGNOSTIC USE: Standardized grass pollen extract may be used to diagnose sensitivity to grass pollen by performing skin tests on persons with a history of grass pollen allergy.

Due to the risk of adverse reactions occuting in highly sensitive persons, it is mandatory to initially test all patients percutaneously using the scratch, prick or puncture method. If a properly performed percutaneous test is negative, an intradermal test may be used with caution. PUNCTURE TEST: The punture test should be performed first with 10,000 BAU/mL extract.

Data for the puncture test using 10,000 BAU/mL extract are summarized in Table 1 under CLINICAL PHARMOCOLOGY. If the puncture test to 10,000 BAU/mL extract is negative, the test may be repeated using 100,000 BAU/mL extract. Appropriate positive and negative controls for skin test interpretation are necessary.

Reactions are quarntified based on size of erythema and wheal in reaction to controls. INTRADERMAL TEST: An intradermal test should only be performed after a puncture test has been properly administered with a negative result. It is usually safe to initiate intradermal testing with a 1:1,000 v/v diluton of the extract to which a negative puncture test was observed.

For example, if a puncture test is done with 10,000 BAU/mL extract and is negative, the intradermal test may be performed with 0.05 mL of 10 BAU/mL extract. The dose may be increased to 0.05 mL of 100 BAU/mL extract if the intradermal test with 10 BAU/mL extract is negative. THERAPEUTIC USE: The dosage of grass pollen extract administered by subcutaneous injection during immunotherapy is highly individualized and varies according to the patient.

In patients who appear to be highly sensitive by history and skin test, the initial dose of the extract should be low, such as 0.1 mL of a

0.01BAU/mL dilution. The amount of extract is increased at each injection, but not more than 50%-100% of the previous amount, and the next increment is governed by the response to the last injection. Local reactions that persist longer than 24 hours are undesirable and any systemic reaction is an indication that the dose should be reduced (at least 50%).

The upper limits of dosage have not been established, but doses larger than 0.2 mL of concentrate containing 50% glycerol may be painful due to the glycerol in the extract. The potency of each standardized grass pollen in a final mixture should not exceed that obtained from using a 10,000 BAU/mL stock concentrate of each grass included in the mix. Concentrate containing 100,000 BAU/mL should be diluted to 10,000 BAU/mL extract before being used to prepare final mixtures, or alternatively, the volume of 100,000 BAU/mL extract added to the mixture should be reduced 10-fold.

The optimum interval between doses of grass pollen extract has not been definitely established. However, as is customarily practiced, injections are given one or two times per week until the maintenance dose is reached. At this time, the injection interval may be increased to 2 weeks, then to 3 weeks and finally 4 weeks.

If the patient does not return for 6 to 8 weeks after the last injection, the dose should be reduced to 50% of the last dose. If longer than 8 weeks, a dose reduction of one, two or three dilutions may be made, depending on the amount of time that has elapsed since the last injection. The dosage and the interval between injections may need to be modified according to the clinical response of the patient.

When switching patients to fresh extract, the initial dose should be reduced 75% [one-quarter (25%) of the previous dose administered from the old lot of extract]. A period of three to five years of injection therapy constitutes an average course of treatmen… [Excerpted — this section continues on DailyMed.]

⛔ Contraindications 177 words ▾

CONTRAINDICATIONS Immunotherapy should not be started in patients until a specific diagnosis of Type I allergy to grass pollen has been made from the patient's allergy history and from a positive skin test to grass pollen extract. Other contraindications include: EXTREME SENSITIVITY TO GRASS POLLEN: Patients who experience serious adverse reactions to grass pollen extract from skin testing and/or immunotherapy should not be given the product. AUTOIMMUNE DISEASE: Individuals with autoimmune disease may be at risk, due to the possibility of routine immunizations exacerbating symptoms of the underlying disease.

MYOCARDIAL INFARCTION: Patients who have experienced a recent myocardial infarction may not be able to tolerate adverse reactions resulting from skin testing or immunotherapy. The benefit-torisk ratio must be carefully evaluated in these patients. CHILDREN WITH NEPHROTIC SYNDROME: Children with nephrotic syndrome require careful consideration and probably should not receive immunotherapy, due to a variety of seemingly unrelated events that may cause an exacerbation of nephrotic disease.

BLEEDING DIATHESIS: Injections of grass pollen extract should not be administered in the presence of diseases characterized by a bleeding diathesis.

⚠️ Warnings ~1 min read ▾

WARNINGS Standardized grass pollen extract must be diluted prior to first use on a patient for immunotherapy or intradermal testing (see DOSAGE AND ADMINISTRATION). Grass pollen extract is manufactured to assure high potency and has the ability to cause serious local and systemic reactions, including death in sensitive patients (14). Patients should be informed of this risk and precautions should be discussed prior to initiating skin testing and immunotherapy (see PRECAUTIONS).

Grass pollen extract should be temporarily withheld from a patient if any of the following conditions exist: (a) severe symptoms of rhinitis and/or asthma; (b) infection or flu accompanied by fever; (c) exposure to excessive amounts of grass pollen allergen prior to a scheduled injection. SWITCHING PATIENTS TO STANDARDIZED GRASS POLLEN EXTRACT: The same precautions that are recommended in switching from an old to a new lot of non-standardized grass pollen extract should be followed in switching from non-standardized to standardized grass pollen extract, i.e., the dose of the new lot of standardized grass pollen extract should be reduced 75% of the dose given from an old lot of non-standardized grass pollen extract.

Under certain circumstances, it may be advisable to compare the relative potency of the standardized and non-standardized extract by side by side skin testing using comparable v/v dilutions of the concentrates. When switching from alum precipitated grass pollen extract to standardized grass pollen extract, the patient should be managed as a new patient coming under treatment for the first time.

🤒 Adverse Reactions ~1 min read ▾

ADVERSE REACTIONS Local reactions consisting of erythema, itching, swelling, tenderness and sometimes pain may occur at the injection site. These reactions may appear within a few minutes to hours and persist for several days. Local cold applications and oral antihistamines may be effective treatment.

For marked and prolonged local reactions, steroids may be helpful. Adverse systemic reactions usually occur within minutes and consist primarily of allergic symptoms such as generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema and hypotension. Less commonly, nausea, emesis, abdominal cramps, diarrhea and uterine contractions may occur.

Severe reactions may cause shock and loss of consciousness and fatalities have occurred (14). The treatment of systemic allergic reactions is somewhat dependent upon the symptom complex. Epinephrine hydrochloride 1:1,000 aqueous, in an adult dose of 0.3 - 0.5 mL (or 0.01 mL per kg. for children) administered subcutaneously in the opposite arm is the immediate treatment of choice.

A tourniquet should be placed above the site of the injection if the injection was done on the extremities. Antihistamines may offer relief of recurrent urticaria, associated skin reactions and gastrointestinal symptoms. Persistent wheezing may necessitate intravenous aminophylline treatment in addition to inhaled bronchodilators.

For profound shock and hypotension, intravenous fluids, vasopressors and oxygen also may be needed. Maintenance of an open airway is critical if upper airway obstruction is present. Corticosteroids may provide benefit if symptoms are prolonged or recurrent.

Serious adverse reactions to this product should be reported to MEDWATCH, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20852-9782. Telephone (800) 332-1088.

🆘 Overdosage 72 words ▾

OVERDOSAGE A strong local reaction to the injection of extract may be treated with oral antihistamines and the local application of a cold compress. The dosage must be reduced and additional extract must not be given until all evidence of the reaction has disappeared. A systemic reaction following the injection of extract must be treated immediately with Epinephrine hydrochloride 1:1,000 aqueous and other measures as appropriate (see ADVERSE REACTIONS, paragraph 3 above).

🧬 Clinical Pharmacology ~2 min read ▾

CLINICAL PHARMACOLOGY It is estimated that grass pollen is responsible for 10 - 30% of all IgE-mediated allergies worldwide (1). Temperate grasses, including Dactylis glomerata (Orchard Grass), Lolium perenne (Rye Grass), Phleum pratense (Timothy Grass) and Poa pratensis (Blue Grass), have practically identical allergenic characteristics. Subtropical grasses, such as Cynodon dactylon (Bermuda Grass), are antigenically distinct from temperate grasses and should be regarded as separate allergenic sources.

For effective testing and treatment with grass pollen extracts, the extracts must be properly selected to represent the allergenic enviornment of the allergic individual (1,2,3,4). Grass pollen extract may have as many as 40 components, of which 5 - 10 may be allergenic. The most important allergens are classified into groups I - VI.

Allergens in these groups account for 90 - 100% of the IgE binding prevalence in the serum of grass pollen allergenic patients (1,5). The pharmacologic action of grass pollen extract used diagnostically is based on the liberation of histamine and other substances when allergens in the extract react with specific IgE antibody attached to mast cells. The release of pharmacologically active mediators from mast cell results in the wheal-flare reaction associated with a positive skin test (6,7).

The basis for the clinical improvement of allergic symptoms following immunotherapy with grass pollen extract is not clearly understood. Several immunologic changes have been demonstrated that might be responsible for the amelioration of allergenic symptoms. These changes include (a) increase in serum IgG antbodies, (b) blunting of the seasonal rise of IgE antibodies, (c) elevation of blocking IgA/IgG antibodies in secretions, (d) reduced basophil reactivity and sensitivity to allergens and (e) reduced in vitro lymphocyte responsiveness to allergens (8).

There is evidence that symptoms are effectively altered only by the administration of the relevant allergen (9,10,11). The results shown in Table 1 were observed with 10,000 BAU/mL reference extract administered to 15 highly sensitive grass allergic persons by the puncture method (data on file at FDA). The intradermal doses (BAU/mL) of grass pollen extracts required to elicit 50 mm sum of erythema are shown in Table 2 (12).

Table 1. Puncture data (bifurcated needle) with 10,000 BAU/mL reference grass pollen extracts. P∑E (mm) P∑E = Sum of erythema of the longest and orthogonal diameters.

P∑W (mm) P∑W = Sum of edema (wheal) of the longest and orthogonal diameters. Reference Pollen FDA lot N Mean Range Mean Range Bermuda E4-Ber 15 90.3 43 - 123 15.7 7 - 31 June E3-Jkb 15 77.3 47 - 107 15.9 6 - 28 Meadow Fescue E4-MF 15 81.1 57 - 115 11.9 7 - 22 Orchard E4-Or 15 84.3 57 - 111 14.1 9 - 19 Perennial Rye E10-Rye 15 92.3 73 - 135 17.5 6 - 36 Redtop E4-RE 15 77.1 42 - 98 14.1 8 - 19 Sweet Vernal E4-SV 15 81.2 28 - 123 15.7 8 - 30 Timothy E6-Ti 15 88.3 51- 109 16.9 8 - 40 Note: Relative potency compared to the U.S.

Reference with potency of 1.0. the U.S. Reference for Bermuda Grass is 10,000 BAU/mL (range: 6,900 - 143,000 BAU/mL). The U.S References for other grasses are 100,000 BAU/mL (range: 69,000 - 143,000 BAU/mL).

📦 How Supplied / Storage and Handling 56 words ▾

HOW SUPPLIED Standardized grass pollen extract containing 10,000 BAU/mL is supplied in 1 and 5 mL dropper vials and in 10 mL, 30 mL and 50 mL multidose vials. Bermuda Grass is only supplied as 10,000 BAU/mL. Other standardized grass pollen extracts are available at 100,000 BAU/mL in 10 mL, 30 mL and 50 mL vials.

📦 Storage and Handling 72 words ▾

STORAGE AND HANDLING The expiration date of standardized grass pollen extract is listed on the container label. The extract should be stored at 2 - 8°C, if possible, and kept in this temperature range during office use. Dilutions of the stock concentrate containing less than 50% glycerol are less stable. If loss of potency is suspected, such dilutions should be checked by skin testing with equal units of a freshly prepared dilution.

📋 Description ~1 min read ▾

DESCRIPTION Standardized grass pollen extract is a sterile solution containing the extractables of grass pollen in 0.25% sodium chloride, 0.125% sodium bicarbonate, 50% glycerol v/v and 0.4% phenol w/v. Standardized grass pollen extracts include Bermuda Grass ( Cynodon dactylon ), June Grass ( Poa pratensis ), Meadow Fescue Grass ( Festuca elatior ), Orchard Grass ( Dactylis glomerata ), Perennial Rye Grass ( Lolium perenne ), Redtop Grass ( Agrostis alba ), Sweet Vernal Grass ( Anthoxanthum odoratum ) and Timothy Grass ( Phleum pratense ).

The extract may be administered by the scratch, prick, puncture, or intradermal methods of skin testing for diagnostic purposes and subcutaneously for therapeutic purposes as directed under Dosage and Administration. The potency of standardized grass pollen extracts is expressed in Bioequivalent Allergy Units per mL (BAU/mL) and is determined by an in vitro ELISA Competition Assay comparing the extract to a U.S. reference grass pollen extract available from the Center for Biologics Evaluation and Research (CBER), U.S.

Food and Drug Administration. Bioequivalent Allergy Units per mL (BAU/mL) have been assigned to the reference extract based on quantitative skin testing (see CLINICAL PHARMACOLOGY). CBER reference extract labeled 100,000 BAU/mL can be diluted 1:5 million and yield a 50 mm sum of erythema diameter response intradermally in highly puncture reactive subjects.

CBER reference extract labeled 10,000 BAU/mL can be diluted 1:500,000 for the same response (12). Allermed's standardized grass pollen extracts labeled in BAU/mL are not interchangeable with alum-precipitated grass pollen extracts, grass pollen extracts labeled in AU/mL or non-standardized grass pollen extracts.

⚠️ Precautions ~2 min read ▾

PRECAUTIONS GENERAL: The risk of a severe allergic reaction usually can be reduced by eliciting the patient's allergy history and by percutaneous testing by the scratch, prick or puncture method. If a scratch, prick or puncture skin test is negative, it usually is safe to perform an intradermal test with a one thousand-fold dilution of the extract used for the percutaneous test. If there is a history of unusual sensitivity, it is advisable to use a weaker dilution of the extract for skin testing.

Systemic allergic reactions may occur as a result of immunotherapy. The risk can be reduced by adherence to a careful injection schedule, which starts with a low concentration of extract and is increased slowly. The physician must be prepared to treat anaphylaxis should it occur and have the necessary drugs and equipment on hand to treat serious adverse reactions.

Extracts should not be administered by the patient or by other individuals who are not prepared to treat anaphylaxis, should it occur. Extract must be injected subcutaneously during immunotherapy. It must not be given intravenously.

A separate sterile tuberculin syringe graduated in 0.01 mL should be used for each injection. INFORMATION FOR PATIENTS: Because most serious reactions occur within 20 minutes after the injection of allergenic extract the patient should remain under observation for this length of time. The patient also should be instructed to report any unusual reactions to the physician, such as swelling and/or tenderness at the injection site or rhinorrhea, sneezing, coughing, wheezing, shortness of breath, nausea, dizziness or faintness following the injection of extract.

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Long term studies in animals have not been conducted with standardized grass pollen extract to determine the potential for carcinogenicity, mutagenicity or impairment of fertility. PREGNANCY CATEGORY C: Animal reproduction studies have not been conducted with standardized grass pollen extract. It is also not known whether standardized grass pollen extract can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

Caution should be exercised in testing or treating pregnant females, because a systemic reaction might conceivably cause uterine muscle contractions leading to abortion. Standardized grass pollen extract should be given to a pregnant woman only if clearly needed (15). PEDIATRIC USE: The dose of allergenic extract recommended for children is the same as for adults.

Allowances may be made in the injection of large doses of extract for treatment. In this case, it may be advisable to modify the dose and frequency of injections, so that the discomfort is minimized. NURSING MOTHERS: It is not known whether standardized grass pollen extract is excreted in human milk.

Because many drugs are excreted in human milk, caution should be exercised when allergenic extract is administered to a nursing woman. DRUG INTERACTION: Antihistamines and hydroxyzine can inhibit the immediate skin test reaction. Patients being treated with delayed absorption antihistamine tablets should be free of such medication for 48 hours before testing.

Non-sedating antihistamines, such as terfenadine and astemizole, may variably suppress the skin response for longer periods of time up to six weeks. Epinephrine injection inhibits the immediate skin test reaction for several hours. Beta-blocking drugs may make a patient refractory to the usual dose of epinephrine, in the event epinephrine is required to treat an adverse allergic reaction.

📚 References ~1 min read ▾

REFERENCES Bierman, C.W., Pearlman, D.S., Shapiro, G.G., Busse, W.W. Allergy, asthma and immunology from infancy to adulthood, Third Edition, p. 533, W.B.

Saunders, Philadelphia, 1996. Martin, B.G., Mansfield, L.E., Nelson, H.S. Cross-allergenicity among the grasses, Ann.

Allergy, 54: 99-104, 1985. Milner, F.H., Tees, E.C. Specific sensitivity to individual grass pollens in some hay fever patients, Clinical Allergy.

2:83, 1972. Frankland, A.W., Augustine, R. Grass pollen antigens effective in treatment, Clinical Science, 23:95, 1962.

Matthiesen, F., Lowenstein, H. Group V allergens in grass pollens. II.

Investigation of group V allergens in pollens from 10 grasses. Clin. Exp.

Allergy, 21:309-320, 1991. Ting, S., Dunsky, E.H., Lavker, R.M., et al. Patterns of mast cell alterations and in vivo mediator release in human allergic skin reactions, J.

Allergy Clin. Immunol, 66:417, 1980. Zweiman, B.

Mediators of allergic inflammation in the skin. Clin. Allergy, 18:419, 1988.

Creticos, P.S. Immunologic changes associated with immunotherapy, Immunol. Allergy Clin., North Am., 12:13-37, 1992.

Lowell, F.C., Franklin, W. A double-blind study of the effectiveness and specificity of injectiontherapy in ragweed hayfever. N.

England J. Med., 273:675-679, 1965. Norman, P.S., Lichtenstein, L.M.

The clinical and immunologic specificity of immunotherapy, J. Allergy Clin. Immunol., 61:370-377, 1978.

Reid, M.J., Moss, R.B., Yoa-Pi, H., et al. Seasonal asthma in northern California: Allergic causes and efficacy of immunotherapy, J. Allergy Clin.

Immunol., 78:590-600, 1986. Turkeltaub, P.C. The allergy unit-clinical relevance: issues in allergen standardization.

In: Lockey, R.F., S.C. Bukantz eds., Allergen Immunotherapy, Marcel Dekkar, New York, 171-190, 1991. Middleton, E.

Jr., Reed, C.E., Ellis, F.E., et al. Allergy Principles and practice, Fourth Edition, Vol. I, 573-594, Vol.

II 1489-1509, Mosby, St. Louis, 1993. Reid, M.J., Lockey, R.F., Turkeltaub, P.C., Platts-Mills, T.A.E.

Survey of fatalities from skin testing and immunotherapy, J. Allergy Clin. Immunol., 92: 6-15, 1993.

Metzger, W.J., Turner, E., Patterson, R. The safety of immunotherapy during pregnancy, J. Allergy Clin.

Immunol., 61:268, 1978.

📄 Package Label / Principal Display Panel 27 words ▾

0309-50_Std Redtop Grass_50mL 0318-10_Std Sweet Vernal Grass_10mL 0342-10_Std Bermuda Grass_10mL 0343-10_Std Orchard Grass_10mL 0350-50_Std Meadow Fescue_50mL 0379-05_Std Perennial Rye Grass_5mL 0386-05_Std Timothy Grass_5mL 0393-05_Std Kentucky Blue Grass_5mL

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Standardized Orchard Grass (this brand).

Top reported reactions

Dyspnoea4
Throat Irritation4
Cough3
Pruritus3
Chest Discomfort2
Eyelid Oedema2
Flushing2

Reporter sex

10 reports
Male · 40%
Female · 60%

Serious outcomes

Hospitalization1
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 2 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Allermed Laboratories, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 10 ml (49643-0343-10), 30 ml (49643-0343-30), 50 ml (49643-0343-50). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Allermed Laboratories, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 49643-0342-05 · Allermed 49643-0344-05 · Allermed →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.